AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00408863
Drug: tibolone
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibolone 2.5 mg/day
Trial: NCT01638013
Drug: Peficitinib
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral Tablet
Trial: NCT03532854
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan P.O
Trial: NCT01730326
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg
Trial: NCT01730326
Drug: Dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg
Trial: NCT03020134
Drug: Ravidasvir
RxNorm normalized name: Ravidasvir
DrugBank: Ravidasvir (DB15652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
Trial: NCT03020134
Drug: Danoprevir
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Trial: NCT03020134
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Trial: NCT04208386
Drug: JNJ-73763989
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 will be administered SC under fasted condition.
Trial: NCT00017654
Drug: anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017654
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017654
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04300517
Drug: Three sachet of protein supplement to be mixed in with water used daily
RxNorm normalized name: purified protein derivative of tuberculin
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sachet of protein supplement to be mixed in with water used daily
Trial: NCT02696733
Drug: lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthetic used to block the obturator nerve
Trial: NCT01231542
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin is approved by the FDA for the treatment of tuberculosis.
Trial: NCT01231542
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin is approved by the FDA for the treatment of tuberculosis.
Trial: NCT02153424
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04135560
Drug: PF-07038124 and Vehicle
RxNorm normalized name: PF-07038124
DrugBank: PF-07038124 (DB19143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
Trial: NCT04135560
Drug: PF-07038124 or vehicle
RxNorm normalized name: edaravone
DrugBank: PF-07038124 (DB19143)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
Trial: NCT04135560
Drug: PF-07038124 or vehicle
RxNorm normalized name: edaravone
DrugBank: PF-07038124 (DB19143)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
Trial: NCT04135560
Drug: PF-07038124 or vehicle
RxNorm normalized name: edaravone
DrugBank: PF-07038124 (DB19143)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
Trial: NCT04135560
Drug: PF-07038124 or vehicle
RxNorm normalized name: edaravone
DrugBank: PF-07038124 (DB19143)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
Trial: NCT04135560
Drug: PF-07038124 or vehicle
RxNorm normalized name: edaravone
DrugBank: PF-07038124 (DB19143)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
Trial: NCT04135560
Drug: PF-07038124 or vehicle
RxNorm normalized name: edaravone
DrugBank: PF-07038124 (DB19143)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-07038124 safe concentration or vehicle BID applied to 10% BSA
Trial: NCT00926731
Drug: LDAC (low dose cytosine arabinoside)
RxNorm normalized name: Cytosine arabinoside
DrugBank: Tildacerfont (DB18545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg subcutaneous injection given twice daily
Trial: NCT01005160
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CKD-501 0.5mg, metformin 1000mg
Trial: NCT01005160
Drug: CKD-501
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-501 0.5mg, metformin 1000mg
Trial: NCT01121848
Drug: OXALIPLATIN
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:
Trial: NCT01121848
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:
Trial: NCT01510145
Drug: Travoprost 0.004% BAK-free
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Containing Polyquad (PQ) preservative
Trial: NCT03162510
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
Trial: NCT03162510
Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 mg/m2 IVD 30 min bi-weekly.
Trial: NCT03162510
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
Trial: NCT00532025
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
Trial: NCT02359357
Drug: FDL169
RxNorm normalized name: FDL169
DrugBank: FDL169 (DB16878)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00592566
Drug: Dexamethasone, desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
Trial: NCT01599507
Drug: FG-4592
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIW dosing, capsule
Trial: NCT00616382
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
Trial: NCT03521232
Drug: Niclosamide
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: enema given twice daily for 6 weeks
Trial: NCT00006164
Drug: Peginterferon alfa-2a + Ribavirin
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks
Trial: NCT00006164
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mcg/week injection, for 3.5 years
Trial: NCT02750345
Drug: Nitisinone
RxNorm normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.
Trial: NCT02750345
Drug: Nitisinone Baked Tablet
RxNorm normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
Trial: NCT02750345
Drug: Orfadin
RxNorm normalized name: Orfadin
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered.
Trial: NCT02591667
Drug: Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;
Trial: NCT01131429
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d per os until proven disease progression
Trial: NCT01131429
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
Trial: NCT01131429
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
Trial: NCT01131429
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
Trial: NCT01131429
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
Trial: NCT01131429
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d per os as second-line treatment
Trial: NCT00608023
Drug: Tesamorelin
RxNorm normalized name: Tesamorelin
DrugBank: Tesamorelin (DB08869)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00608023
Drug: Placebo for Tesamorelin
DrugBank: Tesamorelin (DB08869)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01991080
Drug: Wheatgerm juice
RxNorm normalized name: tamarind juice
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will drink wheatgerm juice
Trial: NCT02068690
Drug: BI 425809 PfOS
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809 PfOS
Trial: NCT02068690
Drug: BI 425809 tablet
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809 tablet
Trial: NCT03781895
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)
Trial: NCT03981887
Drug: Nafithromycin
RxNorm normalized name: Nafithromycin
DrugBank: Nafithromycin (DB16246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafithromycin 200 mg as IV infusion
Trial: NCT02232581
Drug: Alovudine - low
RxNorm normalized name: low-density polyethylene
DrugBank: Alovudine (DB06198)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232581
Drug: Alovudine - medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
DrugBank: Alovudine (DB06198)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232581
Drug: Alovudine - high
RxNorm normalized name: high-density polyethylene
DrugBank: Alovudine (DB06198)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02704702
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00258765
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003191
Drug: fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01636063
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
Trial: NCT01636063
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
Trial: NCT04085458
Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)
RxNorm normalized name: damoctocog alfa pegol
DrugBank: Damoctocog alfa pegol (DB14700)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
Trial: NCT00431522
Drug: Valproic acid, sodium salt
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02259309
Drug: Misoprostol - buccal
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: buccal administration
Trial: NCT02259309
Drug: Misoprostol - vaginal
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vaginal administration
Trial: NCT02013167
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinatumomab is administered as a continuous intravenous infusion (CIV).
Trial: NCT00167141
Drug: injection of hormonal male contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone injections 4 times
Trial: NCT00620178
Drug: Candesartan Cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral once daily dose
Trial: NCT00620178
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily oral dose
Trial: NCT01497990
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
Trial: NCT02146638
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04120753
Drug: Olmesartan 20 mg/Amlodipine 5 mg
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, QD
Trial: NCT05594017
Drug: Scopolamine (0.4mg)
RxNorm normalized name: scopolamine 0.4 MG
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
Trial: NCT01181999
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
Trial: NCT02734771
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02734771
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02734771
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00885586
Drug: gabapentine
RxNorm normalized name: Gabapentine
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
Trial: NCT03397082
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
Trial: NCT01328535
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01709422
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol is the sedative drug used as an additional sedation to one of the study arm.
Trial: NCT01709422
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam is one of the two conventional sedative drugs included in both arms.
Trial: NCT01709422
Drug: Meperidine
RxNorm normalized name: Meperidine
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine is one of the two conventional sedative drugs included in both arms.
Trial: NCT01005316
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Trial: NCT01005316
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Trial: NCT01005316
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
Trial: NCT04313374
Drug: Morphine PCA 1 mg
RxNorm normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
Trial: NCT04313374
Drug: Morphine PCA 0,5 mg
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
Trial: NCT01490736
Drug: Lemuteporfin
RxNorm normalized name: Lemuteporfin
DrugBank: Lemuteporfin (DB04980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lemuteporfin topical solution, 1%
Trial: NCT02130687
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
Trial: NCT02130687
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
Trial: NCT01612286
Drug: endostatin
RxNorm normalized name: Endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles
Trial: NCT00625196
Drug: Fluticasone foroate/ vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
Trial: NCT00625196
Drug: Fluticasone foroate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone (DB13867)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone foroate 800 micrograms will be available as dry powder inhaler.